Anchor, J&J in discovery deal

Anchor Therapeutics Inc. (Cambridge, Mass.) and Ortho-McNeil-Janssen Pharmaceuticals Inc. partnered to use Anchor's pepducin technology to discover and develop therapeutics targeting G protein-coupled receptors (GPCRs) for cancer and metabolic disorders. The deal includes Anchor's preclinical program targeting G protein-coupled receptor 39 (GPR39) for metabolic diseases. The partners will collaborate on discovery and preclinical optimization, after which Ortho-McNeil-Janssen, which is a Johnson & Johnson (NYSE:JNJ) unit, will be responsible for further development and commercialization. ...